Latest Tax Refunds News

Page 3 of 23
Neurotech International has dosed the first patient in its pivotal Phase 3 trial of NTI164, with all six Australian sites now active and up to 200 children planned for enrolment. The milestone sits alongside FDA clearance and fresh funding, but quarter-end cash covered only 1.24 quarters of historical operating outflows.
Ada Torres
Ada Torres
28 Oct 2026
Venari Minerals has funded the next stage of its Red Mountain lithium project after raising $6.1 million, while drilling and permitting advance in Nevada. The company is also testing whether strontium and magnesium can add value beyond lithium carbonate, although commercial recovery remains unproven.
Maxwell Dee
Maxwell Dee
27 Oct 2026
Cynata Therapeutics ended September with just A$175,000 in cash after a A$1.316 million quarterly operating drain, but says sweeping cuts and fresh funding could extend its runway into FY2028. The biotech has now reduced its workforce to zero, repaid its R&D loan and shifted focus to finding value for its Cymerus platform.
Ada Torres
Ada Torres
27 Oct 2026
New Frontier Minerals has strengthened its exploration case at Mt Storm, where surface samples returned up to 6.88% copper, while advancing targets at Eldorado and Harts Range. The sharper investor question is funding: the company ended September with 1.9 quarters of estimated cash coverage and is monitoring options to raise capital.
Maxwell Dee
Maxwell Dee
27 Oct 2026
BluGlass has expanded its customer-funded GaN laser programs with a A$1.4 million Uviquity contract and a new A$286,000 photonics collaboration. But its A$8 million facility is fully drawn, carries 16.5% interest and leaves reported funding coverage at 2.8 quarters.
Victor Sage
Victor Sage
23 Oct 2026
Arovella Therapeutics has received a $4.03 million FY2026 R&D tax refund, giving the clinical-stage biotech additional cash as it advances its lead therapy ALA-101 towards first-patient dosing. The payment arrives without any accompanying clinical data or disclosed update to the company’s cash runway.
Ada Torres
Ada Torres
22 Oct 2026
Invion has secured two financing arrangements that could cover up to approximately 85% of its clinical trial costs, providing support for its skin cancer and planned anogenital cancer programs. The funding comes with potential dilution, 16% interest and conditions that leave the actual amount available dependent on drawdowns and R&D tax refunds.
Victor Sage
Victor Sage
21 Oct 2026
Microba has secured a $2.025 million placement while cutting costs further, launching GI Navigator and advancing its proposed merger with Genetic Signatures. The funding comes as the company reports strong Australian testing growth but only about one quarter of cash cover before the raise.
Victor Sage
Victor Sage
20 Oct 2026
Green360 Technologies has moved MKX further into commercial supply, with binding agreements covering up to 9,600 tonnes and more than 3,500m³ of concrete placed in Melbourne projects. Revenue rose and operating cash outflow narrowed sharply, although the reported contract volumes are maximums rather than guaranteed purchases.
Victor Sage
Victor Sage
20 Oct 2026
Janus Electric has used a A$1.91 million FY2026 R&D tax refund to cut its Rockford loan balance to A$987,000. The repayment is expected to reduce interest costs by about A$325,000 a year, while a further overseas R&D refund remains subject to approval.
Victor Sage
Victor Sage
20 Oct 2026
Beetaloo Energy is approaching a pivotal Q4 milestone, with its Carpentaria Gas Plant moving into final instrumentation and electrical works after Carpentaria-5H sustained an average 6.9 TJ/day flow. The company also ended September with $113.2 million in liquidity and unveiled a longer-term gas-to-power and data centre opportunity near Darwin.
Victor Sage
Victor Sage
20 Oct 2026
Hazer Group has expanded its commercial pipeline through a paid Japanese utility study assessing hydrogen facilities of up to 300,000 tonnes per year, while its KBR alliance advances a standardised commercial-scale design. The company ended September with A$8.3 million in cash and reported A$12.9 million in pro-forma funding, but remains pre-revenue in the quarter.
Victor Sage
Victor Sage
19 Oct 2026

Browse the archive

Full archive